Key Developments: Lonza Group AG (LZAGF.PK)

LZAGF.PK on OTC Markets Group

131.30USD
17 Apr 2015
Change (% chg)

-- (--)
Prev Close
$131.30
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
85
52-wk High
$133.44
52-wk Low
$102.70

Search Stocks

Latest Key Developments (Source: Significant Developments)

arGEN-X announces a multi-product GS Xceed license agreement with Lonza Group
Wednesday, 18 Feb 2015 01:15am EST 

arGEN-X BV:Lonza Group AG and arGEN-X announce a multi-product GS Xceed license agreement for therapeutic antibodies.License secures long-term access for arGEN-X and its strategic partners to Lonza's GS Xceed system for creation and development of cell lines.Now has access to GS Xceed system for development and manufacture of both current and future therapeutic antibody products.  Full Article

TiGenix and Lonza sign agreement for the manufacture of stem cell-based treatment of complex perianal fistulas in Crohn’s Disease
Thursday, 12 Feb 2015 01:17am EST 

Lonza Group AG:Signs an agreement for the supply of TiGenix’s eASC product, Cx601.Under the agreement, Lonza will manufacture material for the Phase 3 trial of Cx601 in the US at Lonza’s cell therapy production facility in Walkersville, Maryland.  Full Article

Lonza Group AG proposes FY 2014 dividend
Wednesday, 21 Jan 2015 01:00am EST 

Lonza Group AG:Board of Directors is proposing increased dividend to 2.50 Swiss francs per share for FY 2014.Dividend for 2013 was of 2.15 Swiss francs per share.  Full Article

Lonza Group AG and Celladon Corporation establish strategic commercial manufacturing collaboration for MYDICAR
Monday, 3 Nov 2014 01:15am EST 

Lonza Group AG:Says Lonza and Celladon Corporation establish strategic commercial manufacturing collaboration for MYDICAR.Lonza to initiate design of new commercial viral therapeutics facility in Portsmouth, NH (USA).Celladon obtains option to trigger construction of facility and commit to long-term commercial supply.Lonza to purchase $10 million of Celladon common stock upon Celladon's decision to trigger construction and commitment for commercial supply.  Full Article

Lonza Group AG confirms FY 2014 EBIT forecast and lowers FY 2014 revenue forecast
Friday, 31 Oct 2014 02:00am EDT 

Lonza Group AG:Sees FY 2014 CORE EBIT growth of about 10 pct, despite the weaker-than-expected Water Treatment results, bringing revenue growth to under 5 pct.FY 2013 revenue 3.584 billion euros.FY 2014 revenue estimate 3.750 million euros - Thomson Reuters I/B/E/S.  Full Article

Lonza Group AG reiterates FY 2014 outlook
Thursday, 24 Jul 2014 01:00am EDT 

Lonza Group AG:Reiterates full FY 2014 outlook with CORE EBIT growth of about 10 pct and sales growth of about 5 pct.  Full Article

Lonza Group AG confirms FY 2014 outlook
Thursday, 24 Apr 2014 02:37am EDT 

Lonza Group AG:Confirms FY 2014 outlook.Says on track to deliver revenue growth of about 5 pct and CORE EBIT growth of about 10 pct in FY 2014.FY 2013 revenue of 3,584 million Swiss francs.  Full Article

Lonza Group AG proposes cash dividend for 2013
Thursday, 23 Jan 2014 01:03am EST 

Lonza Group AG:Says Board of Directors is proposing a cash dividend of 2.15 Swiss Franc per share for 2013.  Full Article

Lonza Group AG issues FY 2014 guidance and sustains mid FY 2015 outlook
Wednesday, 22 Jan 2014 07:00pm EST 

Lonza Group AG:Expects FY 2014 CORE EBIT growth of about 10 pct.Expects FY 2014 revenue growth of approximately 5 pct.FY 2013 revenue of 3,584 million Swiss francs.FY 2014 revenue of 3,893 million Swiss francs - Thomson Reuters I/B/E/S.Says for FY 2015, mid-term targets are unchanged.  Full Article

Lonza Group AG extends partnership with Pharmacyclics Inc to support manufacturing of recently approved Oncology Therapeutic, IMBRUVICA
Monday, 13 Jan 2014 01:31am EST 

Lonza Group AG:Says it has established an agreement with Pharmacyclics Inc. to support the commercial and clinical production of its first-in-class oral oncology drug, IMBRUVICA.Says this agreement follows a multi-year partnership, including the development and clinical manufacturing, which was utilized for Pharmacyclics’ NDA submission and FDA approval of their lead product for oncology treatment.Says under the long term agreement, Lonza continue to support the production of commercial and clinical material.  Full Article

BRIEF-arGEN-X announces a multi-product GS Xceed license agreement with Lonza Group

* Lonza Group AG and arGEN-X announce a multi-product GS Xceed license agreement for therapeutic antibodies

Search Stocks